silodosin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
4151 160970-54-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • silodosin
  • urief
  • urorec
  • rapaflo
  • silodyx
  • silodoshin
an alpha(1a)-adrenoceptor-selective antagonist; structure given in first source
  • Molecular weight: 495.54
  • Formula: C25H32F3N3O4
  • CLOGP: 3.16
  • LIPINSKI: 0
  • HAC: 7
  • HDO: 3
  • TPSA: 97.05
  • ALOGS: -4.65
  • ROTB: 14
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
8 mg O

ADMET properties:

PropertyValueReference
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.23 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 32 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
CL (Clearance) 2.80 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.05 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 3.60 hours Lombardo F, Berellini G, Obach RS
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Bocci G, Oprea TI, Benet LZ
CL (Clearance) 2.38 mL/min/kg Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K
Vd (Volume of distribution) 0.71 L/kg Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2B,AKT3,AXL,BRAF,CAMK2B,CAMK2D,CDK5,CDK9,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,ITK,MAP3K21,MAPK10,MAPK7,MET,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PIM2,PRKDC,TEK 27
kinase-selectivity-class AXL 1
pfas-class PFAS structural alert (1 = True, 0 = False) 1

Approvals:

DateAgencyCompanyOrphan
Oct. 8, 2008 FDA ACTAVIS LABS UT INC
Jan. 29, 2010 EMA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Haematoma 51.81 51.58 14 291 39034 90589108

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Urinary retention 147.91 13.68 123 15489 42091 42563632
Reversible airways obstruction 132.48 13.68 33 15579 570 42605153
Interstitial lung disease 77.66 13.68 118 15494 78344 42527379
Retrograde ejaculation 54.64 13.68 16 15596 519 42605204
Granulomatous rosacea 51.56 13.68 12 15600 153 42605570
Cerebral infarction 51.05 13.68 60 15552 31109 42574614
Mucosal dryness 50.28 13.68 20 15592 1658 42604065
Acute kidney injury 48.35 13.68 263 15349 367074 42238649
Orthostatic hypotension 47.02 13.68 57 15555 30513 42575210
Haematocrit increased 45.18 13.68 21 15591 2546 42603177
Ejaculation failure 43.60 13.68 15 15597 826 42604897
Left atrial dilatation 43.37 13.68 20 15592 2382 42603341
Hyponatraemia 41.37 13.68 105 15507 101357 42504366
Inappropriate antidiuretic hormone secretion 39.71 13.68 39 15573 16502 42589221
Erectile dysfunction 37.58 13.68 46 15566 24867 42580856
Toxicity to various agents 36.84 13.68 19 15593 229117 42376606
Presyncope 36.49 13.68 43 15569 22344 42583379
Haematuria 36.16 13.68 71 15541 57728 42547995
Fall 35.68 13.68 175 15437 234345 42371378
Sopor 35.24 13.68 33 15579 13169 42592554
Pemphigoid 35.19 13.68 31 15581 11436 42594287
Cerebellar ischaemia 32.12 13.68 8 15604 138 42605585
Haemoglobin increased 31.30 13.68 21 15591 5185 42600538
Histamine level increased 30.86 13.68 7 15605 79 42605644
Pneumonia aspiration 30.70 13.68 61 15551 50017 42555706
Bradycardia 30.29 13.68 84 15528 85400 42520323
Hypoparathyroidism 30.23 13.68 11 15601 714 42605009
Face oedema 28.74 13.68 30 15582 13636 42592087
Acute lung injury 27.97 13.68 13 15599 1576 42604147
Cerebral haematoma 27.58 13.68 20 15592 5590 42600133
Subdural haematoma 27.52 13.68 38 15574 23100 42582623
Decreased appetite 27.15 13.68 141 15471 192996 42412727
Anaemia 25.65 13.68 183 15429 280095 42325628
Hepatitis cholestatic 25.15 13.68 24 15588 9800 42595923
Completed suicide 24.97 13.68 3 15609 96462 42509261
Tongue oedema 23.95 13.68 15 15597 3295 42602428
Hepatic function abnormal 23.79 13.68 56 15556 51511 42554212
Hypokalaemia 22.05 13.68 67 15545 71654 42534069
Syncope 21.87 13.68 83 15529 99323 42506400
Vocal cord paralysis 21.74 13.68 10 15602 1184 42604539
Linear IgA disease 21.73 13.68 12 15600 2091 42603632
Dysuria 21.66 13.68 40 15572 31056 42574667
Tryptase increased 21.54 13.68 7 15605 323 42605400
Arrhythmia 21.06 13.68 46 15566 40271 42565452
Generalised oedema 21.02 13.68 27 15585 15309 42590414
Neutrophil percentage decreased 20.90 13.68 7 15605 355 42605368
Neuropathy vitamin B6 deficiency 20.74 13.68 3 15609 0 42605723
Lactic acidosis 20.71 13.68 49 15563 45212 42560511
Drug ineffective 20.10 13.68 142 15470 630055 41975668
Urinary tract infection 19.50 13.68 80 15532 99204 42506519
Band neutrophil percentage increased 19.28 13.68 5 15607 102 42605621
Angle closure glaucoma 19.19 13.68 9 15603 1113 42604610
Rash vesicular 19.05 13.68 13 15599 3300 42602423
Atrioventricular block complete 18.80 13.68 22 15590 11342 42594381
Hypoproteinaemia 18.50 13.68 12 15600 2800 42602923
Blood triglycerides decreased 18.43 13.68 5 15607 122 42605601
Confusional state 18.04 13.68 114 15498 167483 42438240
Cardiac failure 17.84 13.68 82 15530 106774 42498949
Pyelonephritis 17.78 13.68 18 15594 7896 42597827
Eosinophil percentage increased 17.48 13.68 7 15605 590 42605133
Altered state of consciousness 17.16 13.68 35 15577 29224 42576499
Hypovolaemia 16.98 13.68 21 15591 11464 42594259
Cystitis interstitial 16.85 13.68 5 15607 170 42605553
Mucocutaneous disorder 16.66 13.68 5 15607 177 42605546
Lymphopenia 16.63 13.68 29 15583 21534 42584189
Rash maculo-papular 16.51 13.68 40 15572 37463 42568260
Faecal vomiting 16.48 13.68 7 15605 685 42605038
Drug hypersensitivity 16.31 13.68 8 15604 99381 42506342
Hypoparathyroidism secondary 16.09 13.68 5 15607 199 42605524
Skin disorder 16.05 13.68 25 15587 16919 42588804
Hepatocellular injury 15.92 13.68 30 15582 23648 42582075
Acquired haemophilia 15.79 13.68 9 15603 1666 42604057
Psychological trauma 15.44 13.68 5 15607 228 42605495
Tricuspid valve disease 15.38 13.68 5 15607 231 42605492
Pain 15.15 13.68 43 15569 244805 42360918
Hyperbilirubinaemia 14.95 13.68 27 15585 20608 42585115
Band neutrophil count increased 14.83 13.68 5 15607 259 42605464
Cranial nerve injury 14.51 13.68 3 15609 21 42605702
Adenocarcinoma gastric 14.40 13.68 8 15604 1410 42604313
Varicose vein ruptured 14.40 13.68 4 15608 107 42605616
Hypocalcaemia 14.17 13.68 33 15579 30140 42575583
Subacute cutaneous lupus erythematosus 14.04 13.68 8 15604 1480 42604243
Rhabdomyolysis 13.86 13.68 61 15551 77958 42527765
Agranulocytosis 13.85 13.68 33 15579 30579 42575144
Bladder tamponade 13.71 13.68 6 15606 632 42605091

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Urinary retention 162.45 15.26 106 14519 69577 110505097
Reversible airways obstruction 123.91 15.26 34 14591 2465 110572209
Acute kidney injury 114.23 15.26 256 14369 635174 109939500
Interstitial lung disease 110.67 15.26 113 14512 139221 110435453
Hyponatraemia 71.94 15.26 114 14511 217539 110357135
Retrograde ejaculation 69.37 15.26 15 14610 396 110574278
Cerebral infarction 68.56 15.26 56 14569 51782 110522892
Haematuria 65.28 15.26 67 14558 82938 110491736
Inappropriate antidiuretic hormone secretion 61.08 15.26 44 14581 33807 110540867
Granulomatous rosacea 59.98 15.26 12 14613 214 110574460
Left atrial dilatation 55.47 15.26 20 14605 3540 110571134
Bradycardia 53.50 15.26 83 14542 155434 110419240
Anaemia 53.18 15.26 176 14449 546910 110027764
Haematocrit increased 52.47 15.26 21 14604 4938 110569736
Mucosal dryness 51.95 15.26 20 14605 4243 110570431
Orthostatic hypotension 51.23 15.26 53 14572 66196 110508478
Pneumonia aspiration 48.94 15.26 57 14568 81176 110493498
Presyncope 44.99 15.26 43 14582 48844 110525830
Pemphigoid 43.50 15.26 29 14596 19678 110554996
Subdural haematoma 43.26 15.26 37 14588 36417 110538257
Drug hypersensitivity 42.73 15.26 5 14620 454085 110120589
Haemoglobin increased 40.16 15.26 21 14604 9126 110565548
Cardiac failure 39.75 15.26 81 14544 187545 110387129
Pain 39.41 15.26 41 14584 954914 109619760
Decreased appetite 35.08 15.26 140 14485 475706 110098968
Alopecia 34.35 15.26 4 14621 364749 110209925
Rhabdomyolysis 34.26 15.26 59 14566 120342 110454332
Histamine level increased 34.13 15.26 7 14618 142 110574532
Prostatic specific antigen increased 34.03 15.26 21 14604 12490 110562184
Fall 33.45 15.26 163 14462 603319 109971355
Sopor 33.35 15.26 32 14593 36514 110538160
Syncope 33.33 15.26 79 14546 202457 110372217
Joint swelling 32.79 15.26 9 14616 442836 110131838
Hepatic function abnormal 32.58 15.26 49 14576 89246 110485428
Psychological trauma 32.20 15.26 11 14614 1662 110573012
Acute lung injury 32.15 15.26 13 14612 3138 110571536
Atrial fibrillation 31.93 15.26 84 14541 229558 110345116
Benign prostatic hyperplasia 31.30 15.26 23 14602 18211 110556463
Cerebral haematoma 30.95 15.26 18 14607 9614 110565060
Hypokalaemia 30.92 15.26 72 14553 182376 110392298
Face oedema 29.96 15.26 29 14596 33440 110541234
Hepatitis cholestatic 29.80 15.26 22 14603 17544 110557130
Lactic acidosis 29.78 15.26 48 14577 92763 110481911
Arrhythmia 29.50 15.26 41 14584 69534 110505140
Hyperkalaemia 29.20 15.26 59 14566 135737 110438937
Platelet count decreased 28.74 15.26 81 14544 230362 110344312
Erectile dysfunction 28.72 15.26 22 14603 18534 110556140
Ejaculation failure 27.46 15.26 7 14618 381 110574293
Haematoma 27.13 15.26 36 14589 58440 110516234
Hyperbilirubinaemia 26.38 15.26 26 14599 30645 110544029
Generalised oedema 26.35 15.26 26 14599 30678 110543996
Drug ineffective 26.25 15.26 108 14517 1520432 109054242
Rash maculo-papular 26.04 15.26 40 14585 74182 110500492
Altered state of consciousness 26.00 15.26 35 14590 57591 110517083
Hypotension 25.17 15.26 136 14489 523713 110050961
Arthropathy 25.06 15.26 4 14621 287518 110287156
Dysuria 24.80 15.26 35 14590 60196 110514478
Toxicity to various agents 24.21 15.26 17 14608 480538 110094136
Sinusitis 23.98 15.26 5 14620 296683 110277991
Neuropathy vitamin B6 deficiency 23.79 15.26 3 14622 0 110574674
Hypovolaemia 23.70 15.26 21 14604 21653 110553021
Prostate cancer 23.65 15.26 27 14598 37614 110537060
Arthralgia 23.51 15.26 42 14583 779590 109795084
Hypoglycaemia 23.25 15.26 49 14576 116055 110458619
Atrioventricular block complete 23.05 15.26 20 14605 20062 110554612
Vocal cord paralysis 22.65 15.26 10 14615 2996 110571678
Thrombocytopenia 22.06 15.26 98 14527 348787 110225887
Completed suicide 21.98 15.26 3 14622 242378 110332296
Linear IgA disease 21.95 15.26 11 14614 4378 110570296
Neutrophil count decreased 21.89 15.26 49 14576 120892 110453782
Hepatocellular injury 21.70 15.26 30 14595 50612 110524062
Hypoparathyroidism 21.62 15.26 8 14617 1522 110573152
Duodenal ulcer 21.52 15.26 19 14606 19495 110555179
Drug interaction 21.47 15.26 126 14499 500057 110074617
Neutrophil percentage decreased 21.32 15.26 7 14618 936 110573738
Tryptase increased 21.32 15.26 7 14618 936 110573738
Mucocutaneous disorder 20.74 15.26 5 14620 216 110574458
Acquired haemophilia 20.63 15.26 9 14616 2622 110572052
Lymphopenia 20.62 15.26 26 14599 40144 110534530
Rheumatoid arthritis 20.53 15.26 7 14618 299606 110275068
Contraindicated product administered 20.44 15.26 4 14621 248263 110326411
Blood triglycerides decreased 20.39 15.26 5 14620 232 110574442
Tongue oedema 20.30 15.26 13 14612 8243 110566431
Pneumonia bacterial 20.27 15.26 21 14604 26240 110548434
Agranulocytosis 19.89 15.26 32 14593 61728 110512946
Hypoparathyroidism secondary 19.41 15.26 5 14620 284 110574390
Pericarditis 19.20 15.26 3 14622 219111 110355563
Bladder tamponade 18.83 15.26 6 14619 730 110573944
Hypoproteinaemia 18.81 15.26 11 14614 5934 110568740
Infusion related reaction 18.52 15.26 14 14611 381148 110193526
Nasopharyngitis 18.51 15.26 15 14610 394346 110180328
Peripheral swelling 18.19 15.26 16 14609 404018 110170656
Angle closure glaucoma 18.18 15.26 9 14616 3490 110571184
Impaired quality of life 17.96 15.26 21 14604 29996 110544678
Faecal vomiting 17.85 15.26 7 14618 1559 110573115
Eosinophil percentage increased 17.78 15.26 7 14618 1575 110573099
Hyperuricaemia 17.75 15.26 15 14610 14516 110560158
Band neutrophil percentage increased 17.75 15.26 5 14620 399 110574275
Cerebellar ischaemia 17.69 15.26 5 14620 404 110574270
Melaena 17.38 15.26 32 14593 68725 110505949
Acidosis 17.36 15.26 18 14607 22513 110552161
Eosinophilia 17.28 15.26 29 14596 57907 110516767
Hypocalcaemia 17.25 15.26 31 14594 65335 110509339
Nausea 17.05 15.26 95 14530 1235595 109339079
Tricuspid valve disease 16.92 15.26 5 14620 473 110574201
Renal impairment 16.81 15.26 59 14566 188386 110386288
Varicose vein ruptured 16.73 15.26 4 14621 167 110574507
Bile duct cancer 16.57 15.26 6 14619 1074 110573600
Skin disorder 16.29 15.26 24 14601 42889 110531785
Bladder transitional cell carcinoma recurrent 16.12 15.26 4 14621 195 110574479
Cerebral haemorrhage 16.12 15.26 30 14595 64938 110509736
Drug intolerance 16.11 15.26 18 14607 406494 110168180
Lower respiratory tract infection 16.10 15.26 6 14619 243100 110331574
Adenocarcinoma gastric 15.94 15.26 7 14618 2072 110572602
Systemic lupus erythematosus 15.67 15.26 7 14618 254331 110320343
Squamous cell carcinoma of skin 15.57 15.26 15 14610 17188 110557486
Cranial nerve injury 15.54 15.26 3 14622 44 110574630
Paraneoplastic syndrome 15.30 15.26 6 14619 1336 110573338
Subretinal fluid 15.29 15.26 6 14619 1338 110573336

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC G04CA04 GENITO URINARY SYSTEM AND SEX HORMONES
UROLOGICALS
DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY
Alpha-adrenoreceptor antagonists
FDA MoA N0000000099 Adrenergic alpha-Antagonists
FDA EPC N0000175553 alpha-Adrenergic Blocker
MeSH PA D000317 Adrenergic alpha-Antagonists
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018663 Adrenergic Agents
MeSH PA D018674 Adrenergic Antagonists
MeSH PA D058668 Adrenergic alpha-1 Receptor Antagonists
MeSH PA D064804 Urological Agents
CHEBI has role CHEBI:35610 antineoplastic agent

Related Drugs by ATC class:

G04CA Alpha-adrenoreceptor antagonists 8 drugs
alfuzosindoxazosindutasteridefinasteridesolifenacintadalafiltamsulosinterazosin

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Benign prostatic hyperplasia indication 266569009
Orthostatic hypotension contraindication 28651003
Acute nephropathy contraindication 58574008
Hepatic failure contraindication 59927004
Kidney disease contraindication 90708001 DOID:557
Cataract surgery contraindication 110473004
Intraoperative floppy iris syndrome contraindication 418801006




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 13.41 acidic
pKa2 7.96 Basic
pKa3 4.09 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Alpha-1A adrenergic receptor GPCR ANTAGONIST Ki 10.44 CHEMBL CHEMBL
D(2) dopamine receptor GPCR Ki 6 CHEMBL
Alpha-2A adrenergic receptor GPCR Ki 6.17 CHEMBL
Potassium voltage-gated channel subfamily H member 2 Ion channel IC50 5.09 CHEMBL
Multidrug resistance protein 1 Transporter WOMBAT-PK
5-hydroxytryptamine receptor 1A GPCR Ki 7.33 CHEMBL
5-hydroxytryptamine receptor 2B GPCR Ki 5.68 CHEMBL
5-hydroxytryptamine receptor 7 GPCR Ki 6.32 CHEMBL
Alpha-2B adrenergic receptor GPCR Ki 6.11 CHEMBL
D(3) dopamine receptor GPCR Ki 7.14 CHEMBL
Histamine H1 receptor GPCR Ki 5.45 CHEMBL
5-hydroxytryptamine receptor 1B GPCR Ki 6.43 CHEMBL
5-hydroxytryptamine receptor 1D GPCR Ki 7.04 CHEMBL
Alpha-2C adrenergic receptor GPCR Ki 6.44 CHEMBL
D(4) dopamine receptor GPCR Ki 5.80 CHEMBL
Alpha-1D adrenergic receptor GPCR ANTAGONIST Ki 8.70 IUPHAR
Alpha-1B adrenergic receptor GPCR ANTAGONIST Ki 7.70 IUPHAR
Beta-2 adrenergic receptor GPCR Ki 7.48 CHEMBL
Alpha-1A adrenergic receptor GPCR IC50 9.10 CHEMBL

External reference:

IDSource
4028100 VUID
N0000177928 NUI
D01965 KEGG_DRUG
4028100 VANDF
C1870115 UMLSCUI
CHEBI:135929 CHEBI
CHEMBL24778 ChEMBL_ID
DB06207 DRUGBANK_ID
C095285 MESH_SUPPLEMENTAL_RECORD_UI
493 IUPHAR_LIGAND_ID
8043 INN_ID
CUZ39LUY82 UNII
5312125 PUBCHEM_CID
720825 RXNORM
159000 MMSL
26009 MMSL
299655 MMSL
d07354 MMSL
012969 NDDF
441605002 SNOMEDCT_US
442042006 SNOMEDCT_US
A1EMV PDB_CHEM_ID
CUZ39LUY82 INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Silodosin Human Prescription Drug Label 1 27241-144 CAPSULE 4 mg ORAL ANDA 25 sections
Silodosin Human Prescription Drug Label 1 27241-145 CAPSULE 8 mg ORAL ANDA 25 sections
Silodosin HUMAN PRESCRIPTION DRUG LABEL 1 31722-635 CAPSULE 4 mg ORAL ANDA 30 sections
Silodosin HUMAN PRESCRIPTION DRUG LABEL 1 31722-636 CAPSULE 8 mg ORAL ANDA 30 sections
Silodosin Human Prescription Drug Label 1 33342-384 CAPSULE 4 mg ORAL ANDA 26 sections
Silodosin Human Prescription Drug Label 1 33342-385 CAPSULE 8 mg ORAL ANDA 26 sections
Silodosin HUMAN PRESCRIPTION DRUG LABEL 1 42291-777 CAPSULE 4 mg ORAL ANDA 25 sections
Silodosin HUMAN PRESCRIPTION DRUG LABEL 1 42291-778 CAPSULE 8 mg ORAL ANDA 25 sections
Silodosin Human Prescription Drug Label 1 46708-405 CAPSULE 4 mg ORAL ANDA 25 sections
Silodosin Human Prescription Drug Label 1 46708-406 CAPSULE 8 mg ORAL ANDA 25 sections
RAPAFLO HUMAN PRESCRIPTION DRUG LABEL 1 54868-6173 CAPSULE 8 mg ORAL NDA 24 sections
SILODOSIN Human Prescription Drug Label 1 59651-095 CAPSULE 4 mg ORAL ANDA 26 sections
SILODOSIN Human Prescription Drug Label 1 59651-096 CAPSULE 8 mg ORAL ANDA 26 sections
Silodosin HUMAN PRESCRIPTION DRUG LABEL 1 60219-1420 CAPSULE 8 mg ORAL ANDA 25 sections
Silodosin HUMAN PRESCRIPTION DRUG LABEL 1 60219-1421 CAPSULE 4 mg ORAL ANDA 25 sections
Silodosin Human Prescription Drug Label 1 62332-405 CAPSULE 4 mg ORAL ANDA 26 sections
Silodosin Human Prescription Drug Label 1 62332-406 CAPSULE 8 mg ORAL ANDA 26 sections
Silodosin HUMAN PRESCRIPTION DRUG LABEL 1 68180-740 CAPSULE 4 mg ORAL ANDA 24 sections
Silodosin HUMAN PRESCRIPTION DRUG LABEL 1 68180-740 CAPSULE 4 mg ORAL ANDA 24 sections
Silodosin HUMAN PRESCRIPTION DRUG LABEL 1 68180-741 CAPSULE 8 mg ORAL ANDA 24 sections
Silodosin HUMAN PRESCRIPTION DRUG LABEL 1 68180-741 CAPSULE 8 mg ORAL ANDA 24 sections
Silodosin HUMAN PRESCRIPTION DRUG LABEL 1 69238-1420 CAPSULE 8 mg ORAL ANDA 25 sections
Silodosin HUMAN PRESCRIPTION DRUG LABEL 1 69238-1421 CAPSULE 4 mg ORAL ANDA 25 sections
Silodosin HUMAN PRESCRIPTION DRUG LABEL 1 71335-3128 CAPSULE 8 mg ORAL ANDA 26 sections
SILODOSIN HUMAN PRESCRIPTION DRUG LABEL 1 72162-2446 CAPSULE 4 mg ORAL ANDA 17 sections
SILODOSIN HUMAN PRESCRIPTION DRUG LABEL 1 72162-2447 CAPSULE 8 mg ORAL ANDA 17 sections
SILODOSIN Human Prescription Drug Label 1 72205-009 CAPSULE 4 mg ORAL ANDA 26 sections
SILODOSIN Human Prescription Drug Label 1 72205-010 CAPSULE 8 mg ORAL ANDA 26 sections
SILODOSIN HUMAN PRESCRIPTION DRUG LABEL 1 72789-090 CAPSULE 8 mg ORAL ANDA 26 sections
SILODOSIN HUMAN PRESCRIPTION DRUG LABEL 1 72789-351 CAPSULE 4 mg ORAL ANDA 26 sections